Monthly Archives: July 2019

With the approvals of tisagenlecleucel (KYMRIAH™) and axicabtagene ciloleucel (YESCARTA™) last year, chimeric antigen receptor (CAR) T-cell therapies have changed the treatment paradigm for patients with certain hematologic malignancies. What is CAR T-cell therapy? CAR T-cell therapy involves re-engineering a patient’s own T-cells to recognize and eradicate cancer. These T-cells are genetically altered to expressRead more

No more posts
Phone Us Now
Email Us Now